Abstract Alzheimer's disease (AD), also called senile dementia, is the most common
neurological disorder. Around 50 million people, mostly of advanced age, are suffering from …

Alzheimer's disease (AD) is the most common neurodegenerative disorder. Worldwide
prevalence of the disease is estimated at more than 24 million cases. With aging of …

Alzheimer's disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to …

Alzheimer's disease (AD) is the primary cause of dementia and is characterized by the death
of brain cells due to the accumulation of insoluble amyloid plaques, hyperphosphorylation of …

Alzheimer's disease (AD) clinical trials, focused on disease modifying drugs and conducted
in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach …

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June
2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer's …

Alzheimer's disease (AD) and other dementias represent a significant and increasing clinical
challenge. This review highlights current treatment options for AD and the main focusses of …

Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly
failed in clinical trials. Together with numerous reports that amyloid is present in brains from …

Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …

Alzheimer's disease is a devastating neurological disorder that affects more than 37 million
people worldwide. The economic burden of Alzheimer's disease is massive; in the United …